Phase 2 participants (N = 80) | |
---|---|
Treatment duration, weeks | |
Mean (SD) | 167.0 (111.1) |
Min, max | 0.71, 370.4 |
Treatment duration, n (%) | |
< 1 year | 15 (18.8%) |
≥ 1 to < 2 years | 12 (15.0%) |
≥ 2 to < 3 years | 10 (12.5%) |
≥ 3 to < 4 years | 12 (15.0%) |
≥ 4 years | 31 (38.8%) |